secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-088952
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q2 net loss $73.5M ($0.39/sh), NDA for acoramidis filed with PDUFA Nov 29
--------------------------------------------------------------------------------

- Net loss $73.5M ($0.39/sh) vs $157.9M loss a year ago; Q2 revenue $2.2M, H1 revenue $213.3M from Bayer and Kyowa Kirin deals.
- Acoramidis NDA for ATTR-CM accepted; PDUFA date Nov 29, 2024; 42% reduction in composite CVH and ACM events at Month 30.
- Cash, equivalents, marketable securities and short-term restricted cash $587.2M as of June 30, up from $392.6M at Dec 31, 2023.
- Phase 3 FORTIFY study (BBP-418 for LGMD2I/R9) surpassed interim analysis enrollment target; top-line data expected 2025.
- Infigratinib in achondroplasia: +2.50 cm/yr annualized height velocity at Month 18 (p=0.0015), significant body proportionality improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024088952/0000950170-24-088952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024088952/bbio-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-088952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer